Actinium (ATNM) Emerging Growth in the Biotech Sector
Good day everyone,
We are continuing our coverage of, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical stage biopharmaceutical company.
Current price $11.82 per share
ATNM shares have remained green since we alerted them at $11.17 on Wednesday. The Thursday closing price of $11.82 represents a gain of 5.8%.
ATNM has been one of the hottest biopharma stocks over the past month and for good reason. We believe the company’s strong operational performance in Q2 and Q3 has elevated the company’s value. In fact, we think, even at today’s price, ATNM shares are a value.
Renaissance Technologies, Sabby Capital, Ardsley Partners, Citadel Investment Group are hedge funds that have expressed a bullish sentiment toward ATNM shares. Institutions have a higher stake in the company shares than insiders. These hedge funds have experts that evaluate the potential of biopharma companies.
Considerations for ATNM shares:
The shares have crossed their 50 DMA and 200 DMA in a bullish manner.
The shares are trading well below their July high of $19.47/share.
Interim data from the ATNM phase III trial is due soon.
The company has twelve products in development.
The company has a tiny share structure.
ATNM’s AWE, or Antibody Warhead Enabling technology platform, is protected by over 120 issued/pending patents, trade secrets and know-how is being utilized in a collaborative research partnership with Astellas Pharma, Inc. (market cap $25 billion).
ATNM’s ARCs for targeted conditioning are intended to potentially enable improved access to cell-based therapies with curative potential, including BMT, or bone marrow transplant, ACT, or adoptive cell therapy such as CAR-T, and Gene Therapy.
The conditioning performed is the act of depleting certain blood and immune-forming cells, including bone marrow stem cells and, in some cases, diseased cells prior to transplanting new cells into a patient.
Currently, conditioning is accomplished using a combination of chemotherapeutic agents and external radiation. These non-targeted conditioning regimens may prevent a patient from receiving a potentially curative therapy and hinder outcomes due to their toxicities. ARCs have the potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while sparing normal healthy cells.
Actinium seems to be on the cusp of becoming a much larger biopharma company. Their AWE delivery system for the delivery of cell destroying pulses may be a major development in the efficacy of many different therapeutic endeavors, even with other companies using it.
We expect their new R&D facility in New York to be a major step in their product development and we further expect the ATNM market cap to grow significantly in step with many catalysts anticipated to come in the near term.